Phathom Pharmaceuticals (PHAT) Liabilities and Shareholders Equity (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $305.1 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $305.1 million, up 3.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (down 23.51% YoY), and the FY2025 annual result was $259.1 million, down 31.5% from the prior year.
• Liabilities and Shareholders Equity climbed to $305.1 million in Q1 2026 per PHAT's latest filing, from $259.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $413.8 million in Q4 2023 and troughed at $144.0 million in Q1 2023.
• A 5-year average of $269.4 million and a median of $259.1 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity tumbled 39.5% in 2022, then jumped 151.1% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $164.8 million in 2022, then jumped by 151.1% to $413.8 million in 2023, then dropped by 8.58% to $378.3 million in 2024, then plunged by 31.5% to $259.1 million in 2025, then advanced by 17.74% to $305.1 million in 2026.
• Business Quant data shows PHAT's Liabilities and Shareholders Equity at $305.1 million in Q1 2026, $259.1 million in Q4 2025, and $240.3 million in Q3 2025.